Loading clinical trials...
Loading clinical trials...
A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Conditions
Interventions
CPI-613 + Hydroxychloroquine
Locations
8
United States
City of Hope
Duarte, California, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
University of Michigan
Ann Arbor, Michigan, United States
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States
Clevland Clinic
Ohio City, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
Start Date
September 1, 2021
Primary Completion Date
March 9, 2023
Completion Date
March 9, 2023
Last Updated
May 24, 2023
Lead Sponsor
Cornerstone Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions